Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin and Pemetrexed in Recurrent Platinum-Sensitive Ovarian Cancer
NCT00230542Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2005
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Response Rate at 2 years. Started Sep 2005; status: completed.
02
Drugs
pemetrexed
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00230542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230542.